Moderna got some things wrong in its development and commercialization of Spikevax for COVID-19, CEO Stéphane Bancel said during the firm’s presentation on 13 January at the J.P. Morgan Healthcare Conference in San Francisco. But the company is still looking ahead rather than dwelling on the past, especially as it builds out its late-stage pipeline and plots out how it will work with the incoming US presidential administration.
CEO Bancel Says Moderna Was ‘Too Logical’ On COVID-19 Vaccinations
Company Sees Lower Sales In 2025
The chief exec said Moderna plans to work with the incoming Trump administration, but implied hope that US regulatory agencies would heed the scientific consensus on vaccines and focus on risk-benefit.
More from J.P. Morgan
• By
Bristol Myers Squibb has been in a rapid growth phase to make up for upcoming losses of exclusivity. Scrip spoke with executives about further catalysts coming in the next 18-24 months.
• By
Lilly’s revenue is rising rapidly based on its successes in diabetes and obesity, and the company is reinvesting in big plays in those markets as well as in cancer, lipid-lowering and other indications.
• By
Despite a big market opportunity with an underserved patient population, investment in the therapeutic area lags and investor perception is a pressure point.
• By
Repatha was not an overnight success, but the work Amgen has done to turn its PCSK9 inhibitor into a blockbuster is informing its strategy for Lp(a)-reducing olpasiran and obesity drug MariTide.
More from Business
• By
The latest in a long line of restructuring measures will see Sumitomo Pharma making a stepped sale of its pharma operations in Asia to major Japanese trading house Marubeni.
• By
CEO Kris Elverum told Scrip about the start-up’s platform for editing RNA to correct genetic variants that cause harm and to reproduce healthy variants as a means of treating disease.
• By
Pharma executives and investors are waiting with bated breath to find out if President Trump will include drugs in a new round of tariffs to be announced on 2 April.